Annual revenue for 2025 up 43% to €3.2 million, in line with annual targets

- Financial targets achieved: revenue up 43% compared to 2024, driven by strong international sales performance for Myrian®
- Continued innovation strategy with several certifications strengthening the product portfolio

Montpellier, France, February 5, 2025, 5:45 pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in AI-enhanced medical imaging solutions that facilitate diagnosis, decision-making, and therapeutic follow-up, publishes its consolidated revenue for the 2025 financial year.

Stephen Armand, Chief Executive Officer of Intrasense, comments:
"2025 marks a turning point for Intrasense, with revenue rising after several years of decline. This growth is in line with our strategic roadmap and confirms the commitment of our teams. We have also developed our commercial and international approach to maximize the impact of our products on our markets. The order intake recorded in 2025 will secure part of our business for 2026. Finally, the CE markings obtained for Myrian® 2.14.x, Liflow® (version 3.x), DUOnco™ Bone (version 1.x) and DUOnco™ Pancreas (version 1.x) contribute to strengthening the value of our product portfolio and support our growth momentum."

Sales up 43%, driven by the Myrian® product line

IFRS Sales	**Published data**			At constant exchange rates	
Year	**2025**	2024	Change	2025	Change
1st half-year	**1 603**	1 203	+33%	1 616	+34%
2nd half-year	**1 612**	1 043	+55%	1 620	+55%
TOTAL	**3 216**	2 246	+43%	3 236	+44%

In 2025, Intrasense achieved its sales target with revenue of €3.2 million, up +43% compared to the previous year. This performance is in line with the €3.0 million announced in mid-December, reflecting Intrasense's strong execution through the end of the year. This includes three sales made with Guerbet in Italy as part of the distribution partnership signed in the first quarter of 2025.

In 2025, Intrasense also achieved its order intake target, with a record amount for the company of more than €6.1 million recorded (this figure includes multi-year licensing and maintenance contracts). This positive performance secures a backlog of just over €3.0 million for the period 2026-2029, providing good visibility into future activity.

IFRS Sales	**Published data**			At constant exchange rates	
Year	**2025**	2024	Change	2025	Change
France	**1 111**	982	+13%	1 111	+13%
Europe	**1 369**	329	+316%	1 369	+316%
China	**261**	425	-39%	270	-37%
Other regions	**475**	510	-7%	486	-5%
TOTAL	3 216	2 246	+43%	3 236	+44%

The geographical breakdown of revenue generated in 2025 highlights the following:

- In France, business grows by +13% to €1.1 million, driven by direct sales and sales through partners, including new licenses and maintenance contracts. The region recorded three sales of Myrian® with the AI Prostate option.
- In Europe, commercial growth remains strong in the second half of the year, with business up 316% to €1.4 million. This performance was driven by the strengthening of the sales team, announced when the strategic roadmap was published.
- In China, in line with the roadmap announced in March, activity is down 39%. The divestment of Intrasense's operations in this region is ongoing.
- In other regions, business declines by a limited 7% to €0.5 million, impacted by lower sales in Japan, partially offset by Latin America, particularly Brazil, where sales remain strong in partnership with a major player in healthcare management software.

Excluding China, Intrasense's revenue grew to its highest level in three years.

An evolving product roadmap to support growth

In 2025, Intrasense adjusted its commercial approach and pivoted towards artificial intelligence marketplaces in imaging to rapidly expand market access. As part of this, the Company signed a contract with deepc, an AI platform, marking a key milestone in this repositioning. Intrasense also revised its strategic roadmap to enhance the value of its portfolio of solutions and support its commercial dynamic.

Myrian®, the Group's flagship solution, is performing strongly commercially, backed by a solid installed base. After several years of sustained R&D development, the Company intends to capitalize on field feedback analysis and maintain a high level of customer satisfaction. This approach focuses on targeted functional updates to optimize the use and deployment of the solution in routine clinical practice.

Concerning the Liflow® solution, Intrasense is currently continuing its Controlled Release phase at several pilot centers. Although the regulatory steps have been successfully completed, the commercial adoption of Liflow® is progressing at a slower pace than initially anticipated. This situation is mainly due to challenges related to technical integration, as well as the need to strengthen its operational robustness to meet high market expectations. In this context, priority is being given to in-depth analysis of field feedback for the first part of 2026.

Finally, the DUOnco™ range of AI solutions, co-developed with Guerbet, shows very encouraging prospects. After completing key regulatory milestones in 2025 with the award of two CE markings, initial commercial approaches are highlighting significant clinical interest. Intrasense is already engaged in advanced discussions with several industrial partners, both in France and internationally.

Participation in major events in 2026

Intrasense intends to continue participating in major conferences and events in 2026, in close collaboration with Guerbet. Unless new strategic priorities arise, the Intrasense teams will be present at:

- ECR (European Congress of Radiology), in Vienna (Austria)
- ESGAR (European Society of Gastrointestinal and Abdominal Radiology), in Montpellier (France)
- JFR (Journées Francophones de la Radiologie), in Paris (France)
- RSNA (Radiology Society of North America), in Chicago (United States)

These strategic events provide an opportunity to present the latest innovations and engage with customers and industrial partners. They will also enable the organize special discussions with participants, particularly through dedicated interaction and presentation formats.

Next financial announcement:
2025 annual results: March 11 (after market close)

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.
Intrasense Product portfolio includes Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, which optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers AI for the detection of pancreatic lesions, focal liver lesions, and the world's first CE-marked AI dedicated to bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AI, optimizes the longitudinal monitoring of cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management. **More information on www.intrasense.fr**

Contacts

INTRASENSE
Communication Officer
Salomé Sylvestre
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

SEITOSEI.ACTIFIN
Investor relations
Foucauld Charavay
Phone: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press relations
Isabelle Dray
Phone: +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com